Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–574 of 574 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Steatosis of Liver Clear all
Completed Not applicable Interventional Results available

Dietary Treatment Study of Pediatric NAFLD

NCT02513121
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Dietary modification
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
11 Years to 16 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
San Diego, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regulation of FGF21 by Nutritional Challenges

NCT00968747
View directory record Official record
Conditions
Fasting, Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Fasting, Diet, oral carbohydrate challenge
Behavioral · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 14, 2026, 7:35 AM EDT
Completed No phase listed Observational

Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery

NCT01007955
View directory record Official record
Conditions
Morbid Obesity, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 14, 2026, 7:35 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
Interventions
GSK4532990, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
80
States / cities
Homewood, Alabama • Chandler, Arizona • Mesa, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 7:35 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214
View directory record Official record
Conditions
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Placebo (PB)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
6
States / cities
Glendale, California • Los Angeles, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NCT03912532
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
36
States / cities
Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Liver and Fat Regulation in Overweight Adolescent Girls

NCT02157974
View directory record Official record
Conditions
Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions
Byetta 5Mcg Pen Injection
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 14, 2026, 7:35 AM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

NCT04880187
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
AXA1125, Placebo
Drug
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 14, 2026, 7:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

NCT06836609
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Interventions
ALN-CIDEB, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chandler, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 14, 2026, 7:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway

NCT03480594
View directory record Official record
Conditions
Fatty Liver
Interventions
MRI Tracer
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 14, 2026, 7:35 AM EDT
Not yet recruiting Phase 1 Interventional

Human Models of Selective Insulin Resistance: Pancreatic Clamp

NCT06558422
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 7:35 AM EDT
Completed No phase listed Observational Results available

Controlled Attenuation Parameter (CAP) in Liver Allografts

NCT02798861
View directory record Official record
Conditions
Liver Transplant, Liver Steatosis, Liver Disease, Primary Non-function, Early Allograft Dysfunction
Interventions
Fibroscan 402/530
Device
Lead sponsor
Andres Duarte-Rojo
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Little Rock, Arkansas • Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 14, 2026, 7:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations

NCT03726827
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver, Fatty Liver
Interventions
Fibroscan screening
Other
Lead sponsor
Fatty liver Foundation
Other
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Texas City, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 14, 2026, 7:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study in NASH to Assess IVA337

NCT03008070
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Madison, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Not applicable Interventional

Effects of a Low Glycemic Load Diet on Fatty Liver in Children

NCT00480922
View directory record Official record
Conditions
Hepatic Steatosis
Interventions
Low glycemic load diet, Low fat diet
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Not applicable Interventional Results available

Effect of Whole Fruit on Glycemic Control in Adults With Type 2 Diabetes

NCT03758742
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
High-Fruit Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
20 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 14, 2026, 7:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis

NCT06993454
View directory record Official record
Conditions
Type 2 Diabetes, Hepatic Steatosis
Interventions
Magnetic Resonance Liver Assessment, Bike Exercise VO2max, DEXA
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
25 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

NCT04521114
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Placebo, leronlimab 700 mg, leronlimab 350 mg
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Coronado, California • Maitland, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 14, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 14, 2026, 7:35 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 14, 2026, 7:35 AM EDT